Charles River Laboratories to Present at William Blair and Jefferies Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 45 th Annual Growth Stock Conference on Tuesday, June 3 rd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 4 th, at 10:30 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends.
A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for approximately two weeks.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 hours ago
- Business Wire
ABL Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abacus Global Management, Inc. ('Abacus' or 'the Company') (NASDAQ: ABL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abacus is the subject of a report issued by Morpheus Research on June 4, 2025, titled: 'Abacus Global Management: This $794 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue by Systematically Underestimating When People Will Die.' According to the report, the Company changed its portfolio valuation methodology to make it appear more profitable than it actually is. The report also alleges that the Company uses unusual methodologies to calculate life expectancy estimates and its co-founders have 'red flags' in their past. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
6 hours ago
- Business Wire
BF-A, BF-B Investors Have Opportunity to Join Brown-Forman Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brown-Forman Corporation ('Brown-Forman' or 'the Company') (NYSE: BF-A, BF-B) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Brown-Forman reported its financial results for fiscal year 2025 on June 5, 2025. The Company reported a decline in year-over-year sales of 7.3% and earnings per share below consensus estimates. The Company stated its "results did not meet our long-term growth aspirations," and advised investors that "looking ahead to fiscal 2026, we expect continued headwinds." If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
7 hours ago
- Yahoo
Why The Mosaic Company (MOS) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where The Mosaic Company (NYSE:MOS) stands against other Friday's worst-performing stocks. Shares of The Mosaic Company decreased by 4.40 percent on Friday to end at $34.80 apiece, a third straight day, as investors reacted negatively to lower production guidance for the second quarter and full year 2025. In a statement, The Mosaic Company (NYSE:MOS) said it now sees phosphate sales volumes for the second quarter of 2025 to be in the range of 1.5 million to 1.6 million tons, or lower than the 1.7 million to 1.9 million tons as targeted previously. A farmer tending to his crops in a field, with a fertiliser bag nearby. It also revised its production guidance for the full year period to 7 million to 7.3 million tons, lower than the 7.2 million to 7.6 million tons as expected previously. While its phosphate facility in New Wales was expected to increase over 20 percent in the current quarter, commissioning and ramp-up of the first of three new gypsum handling systems took longer than expected. The Mosaic Company (NYSE:MOS) said it now expects the second and third systems to be installed and commissioned by the end of June and early July. Additionally, it extended planned downtimes for its Riverview facility to eliminate bottlenecks, causing production to miss initial expectations. Its Louisiana facilities also discovered additional necessary repairs, resulting in extended outage periods and some lost production. Overall, MOS ranks 8th on our list of Friday's worst-performing stocks. While we acknowledge the potential of MOS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
